Predictive Modeling Using a Somatic Mutational Profile in Ovarian High Grade Serous Carcinoma

被引:11
作者
Sohn, Insuk [1 ]
Sung, Chang Ohk [2 ]
机构
[1] Samsung Canc Res Inst, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
来源
PLOS ONE | 2013年 / 8卷 / 01期
关键词
CROSS-VALIDATION; BRCA2; SURVIVAL; CHEMOTHERAPY; ACCURACY; OUTCOMES;
D O I
10.1371/journal.pone.0054089
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Recent high-throughput sequencing technology has identified numerous somatic mutations across the whole exome in a variety of cancers. In this study, we generate a predictive model employing the whole exome somatic mutational profile of ovarian high-grade serous carcinomas (Ov-HGSCs) obtained from The Cancer Genome Atlas data portal. Methods: A total of 311 patients were included for modeling overall survival (OS) and 259 patients were included for modeling progression free survival (PFS) in an analysis of 509 genes. The model was validated with complete leave-one-out cross-validation involving re-selecting genes for each iteration of the cross-validation procedure. Cross-validated Kaplan-Meier curves were generated. Cross-validated time dependent receiver operating characteristic (ROC) curves were computed and the area under the curve (AUC) values were calculated from the ROC curves to estimate the predictive accuracy of the survival risk models. Results: There was a significant difference in OS between the high-risk group (median, 28.1 months) and the low-risk group (median, 61.5 months) (permutated p-value <0.001). For PFS, there was also a significant difference in PFS between the high-risk group (10.9 months) and the low-risk group (22.3 months) (permutated p-value <0.001). Cross-validated AUC values were 0.807 for the OS and 0.747 for the PFS based on a defined landmark time t = 36 months. In comparisons between a predictive model containing only gene variables and a combined model containing both gene variables and clinical covariates, the predictive model containing gene variables without clinical covariates were effective and high AUC values for both OS and PFS were observed. Conclusions: We designed a predictive model using a somatic mutation profile obtained from high-throughput genomic sequencing data in Ov-HGSC samples that may represent a new strategy for applying high-throughput sequencing data to clinical practice.
引用
收藏
页数:7
相关论文
共 25 条
  • [1] Genomic data sampling and its effect on classification performance assessment
    Azuaje, F
    [J]. BMC BIOINFORMATICS, 2003, 4 (1)
  • [2] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [3] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    Bookman, MA
    Darcy, KM
    Clarke-Pearson, D
    Boothby, RA
    Horowitz, IR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 283 - 290
  • [4] The genesis and evolution of high-grade serous ovarian cancer
    Bowtell, David D. L.
    [J]. NATURE REVIEWS CANCER, 2010, 10 (11) : 803 - 808
  • [5] Is cross-validation valid for small-sample microarray classification?
    Braga-Neto, UM
    Dougherty, ER
    [J]. BIOINFORMATICS, 2004, 20 (03) : 374 - 380
  • [6] BRCA1 and BRCA2:: chemosensitivity, treatment outcomes and prognosis
    Foulkes, William D.
    [J]. FAMILIAL CANCER, 2006, 5 (02) : 135 - 142
  • [7] Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
    Gallagher, D. J.
    Konner, J. A.
    Bell-McGuinn, K. M.
    Bhatia, J.
    Sabbatini, P.
    Aghajanian, C. A.
    Offit, K.
    Barakat, R. R.
    Spriggs, D. R.
    Kauff, N. D.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (05) : 1127 - 1132
  • [8] Time-dependent ROC curves for censored survival data and a diagnostic marker
    Heagerty, PJ
    Lumley, T
    Pepe, MS
    [J]. BIOMETRICS, 2000, 56 (02) : 337 - 344
  • [9] Survival model predictive accuracy and ROC curves
    Heagerty, PJ
    Zheng, YY
    [J]. BIOMETRICS, 2005, 61 (01) : 92 - 105
  • [10] Estimation of prediction error variances via Monte Carlo sampling methods using different formulations of the prediction error variance
    Hickey, John M.
    Veerkamp, Roel F.
    Calus, Mario P. L.
    Mulder, Han A.
    Thompson, Robin
    [J]. GENETICS SELECTION EVOLUTION, 2009, 41